InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,011.12
(
-0.22%
)
US TECH 100
16,912.00
(
-0.71%
)
Dow Jones
37,775.38
(
0.06%
)
Brent Oil
86.42
(
-0.66%
)
Bitcoin
63,649.74
(
3.86%
)
Post# of 251523
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

haysaw

Send PM Follow Ignore
Followers 14
Posts 2972
Boards Moderated 0
Alias Born 07/19/2006

haysaw

Re: haysaw post# 202221

Monday, 09/26/2016 10:00:48 AM

Monday, September 26, 2016 10:00:48 AM

Post# of 251523
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

GlobeNewswire•September 26, 2016
- Primary endpoint achieved in both Epidiolex doses with high statistical significance compared to placebo -
- Today’s data represents the third positive Phase 3 pivotal trial for Epidiolex reported in 2016 -

- Data reinforce the potential of Epidiolex to be an important new medicine for patients who suffer from this treatment-resistant childhood-onset epilepsy -
- Company to hold investor conference call today at 8:00 a.m. EDT/13:00 BST -

http://finance.yahoo.com/news/gw-pharmaceuticals-announces-second-positive-105700589.html

Messages posted by individuals may be misleading, deceptive, or in error. If you disagree with a posting, feel free to voice your opinion. It is the policy of iHub to allow our members to freely discuss issues in a free and open manner

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up